A Study of the Implementation, Safety, and Outcomes of OB Nest Model of Care for Expectant Mothers

Overview

About this study

The purpose of this study is to test the safety, patient-reported results, and the adoption into practice of a new model of prenatal care called OB Nest. OB nest is intended to create an experience for patients that feels more connected and patient-centered, allowing the patient to visit the clinic less frequently while offering increased communication with the OB nurses and providers through new tools provided to the patient.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • 18+ years of age
  • Documented gestational age less than 13 weeks
  • Pregnancy documented as low risk (see high risk exclusion criteria below)
  • Able to read and understand English
  • Able to provide informed consent (i.e. no impairments or barriers)

Exclusion Criteria

  • Clinical judgment determines the pregnancy is at high risk for complications
    • Severe hypertension >160/110
    • Possible ectopic
    • Congenital adrenal hypertension
    • Prior PE/DVT/stroke
    • Anticoagulation during prior pregnancy (e.g. antiphospholipid antibody syndrome)
    • Prosthetic heart valve (non-bio)
    • Pulmonary hypertension
    • Mothers currently taking
      • Immunosuppressants
      • Prednisone > 10mg per day
      • Antipsychotic (e.g. lithium, Haldol, Zyprexa)
      • Chemotherapy
    • Recurrent pregnancy loss (>2 losses)
    • Current maternal malignancy
    • Prior myocardial infarction/cardiomyopathy
    • Bio-prosthetic heart valves
    • Marfan syndrome
    • Active liver disease (e.g. hepatitis)
    • Congenital heart disease
    • Coagulopathies including thrombophilias and bleeding disorders
    • Pre-existing diabetes
    • Genetic disease/CF testing/anomalies in prior child
    • Incompetent cervix (prior cerclage)
    • Triplets or quads diagnosed by REI or ultrasound
    • Isoimmunization (Rh, Kell, etc.)
    • History of transplant or currently on Dialysis
    • Recurrent pregnancy loss (antiphospholipid antibody syndrome or collagen vascular disease)
    • Chronic hypertension
    • Prior 2nd or 3rd trimester loss
    • HIV
    • Inflammatory bowel disease
    • Asthma and currently on steroid to control disease

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Abimbola Famuyide, M.B.B.S.

Closed for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions